TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis ; day:07 ; month:01 ; year:2025
South Asian journal of cancer ; (07.01.2025)
- Beteiligte Personen und Organisationen
-
Joarder, Ritam
Patel, Dhwani
Tiwari, Atul
Choudhary, Jatin
Vana, Pranaya
Shenoy, Vallish
Mer, Neha
Ramaswamy, Anant
Bhargava, Prabhat
Ostwal, Vikas
- DOI
-
10.1055/s-0044-1801347
- URN
-
urn:nbn:de:101:1-2502271038370.948295552446
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Joarder, Ritam
- Patel, Dhwani
- Tiwari, Atul
- Choudhary, Jatin
- Vana, Pranaya
- Shenoy, Vallish
- Mer, Neha
- Ramaswamy, Anant
- Bhargava, Prabhat
- Ostwal, Vikas
Ähnliche Objekte (12)
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease
Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
TAS
TAS
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease
Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
TAS
TAS
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease
Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
Intra Peritoneal Chemotherapy in Epithelial Ovarian Cancers
TAS